drugset / Trial / NCT04275232

Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis

NCT04275232 ↗

Phase 3 Enrolling by invitation 1 enrolled Dorothy Bautista, MD Canadian Blood Services · collab
NaSingle-groupOpen-labelTreatment

Summary

Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator to Canadian Blood Services, as approved by Health Canada.

Timeline

Start
2025-05
Primary completion
2025-10
Completion
2025-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogenic plasma aliquots Unknown 2 unknown Topical